Egetis Therapeutics & Anovo Unite for MCT8 Patients
January 2, 2024
Egetis Therapeutics is an innovative pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
What is MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)?
MCT8 deficiency, a rare and debilitating disorder also known as Allan-Herndon-Dudley Syndrome, poses significant challenges for affected individuals and their loved ones. This genetic condition primarily affects brain development and function, leading to developmental delays, muscle weakness, and neurological impairments. Despite its rarity, the impact of Allan-Herndon-Dudley Syndrome is profound, underscoring the urgent need for effective treatments and interventions to improve the quality of life for those affected.
Egetis Therapeutics Partners with Anovo
At Anovo, we’re proud to work with Egetis Therapeutics to help more patients access their innovative new therapy for MCT8 deficiency. Since there is currently no available approved treatment for MCT8 deficiency, our partnership enables us to administer the Egetis Early Access Program (EAP), providing hope and support to patients and families facing the challenges of MCT8 deficiency. Together, we’re committed to advancing the field of rare disease treatment, working towards a brighter future for our patients and their caregivers.
Related Posts
Pyros and Anovo Partner to Elevate Care for Infantile Spasms
Pyros Pharmaceuticals works to elevate the standard of care for children with rare disease by pioneering treatment options like VIGPODER™…
April 1, 2024
Jill’s Story: Advocating for Patients with Acromegaly
Jill Sisco isn’t just an advocate – she’s also a patient herself. She’s been living with Acromegaly, a rare disease…
March 6, 2024
Celebrating Five Consecutive Years as a Top Workplace at Anovo
We are thrilled to announce that Anovo has been recognized as a top workplace by The Commercial Appeal for the…
February 6, 2024